Possis Medical
This article was originally published in The Gray Sheet
Executive Summary
Raises $6 mil. in private placement financing to expand marketing of the AngioJet thrombectomy system for coronary arteries following FDA approval in March. Possis clarifies that while use of the system requires placement of a temporary pacing catheter, "this is not unusual in cardiovascular devices," as was implied by "The Gray Sheet" (March 22, p. 17). A price comparison with Boston Scientific's $600 Oasis thrombectomy catheter (March 22, p. 16) should have noted that the AngioJet model comparable to Oasis also is $600. Both products require purchase of a separate drive unit